Clinical Features of Extragastrointestinal Stromal Tumor Compared with Gastrointestinal Stromal Tumor: A Retrospective, Multicenter, Real-World Study
Authors:
Open Access
- 13 December 2021
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-9
Abstract
Importance. Extragastrointestinal stromal tumor (EGIST) is a rare tumor, and its diagnosis and treatment strategy lack clinical guideline and relative literature evidence. In clinical practice, EGIST only misuses the pattern of GIST of diagnosis and treatment. The study hopes to find evidence of the treatment pattern for EGIST. Objective. This study aimed to compare the tumor characteristics and long-term outcomes between EGIST and GIST. The confounding function was applied to improve the result credibility in the case of small sample size. Design, Setting, and Participants. This cohort study enrolled 55 patients with EGIST who underwent surgery and were selected from four high-volume hospitals in China and 221 GIST patients who were collected from one of the four hospitals between January 2006 and September 2017. We used propensity score matching (PSM) and subgroup analysis to compare EGIST with GIST in terms of prognosis. The confounding function was used for sensitivity analysis to reduce unmeasured confounding. Results. We matched 43 patients in each of the GIST and EGIST groups by PSM. We compared EGIST data with GIST data to explore the prognostic factors between them. In the multivariate Cox regression model, tumor location of EGIST was negatively correlated with overall survival (after PSM: HR, 4.32; 95% CI, 1.22–15.26) or disease-free survival (after PSM: HR, 9.79; 95% CI, 2.22–43.31), which was also intuitively shown in the Kaplan–Meier survival curves (all values < 0.05). In the subgroup analysis, EGIST with high risk factors had a worse prognosis than GIST. In unmeasured confounding analysis, the overall curve tends to show all combinations of c(0) of c(1) up to 2.0, none of which would bring the corrected relative risk to 1 for OS and DFS. Conclusions and Relevance. EGIST was associated with worse prognosis compared with GIST patients, particularly in EGIST patients with high risk factors, while there was a similar prognosis without those high risk factors.Keywords
Funding Information
- Guangdong Provincial People's Hospital (KJ012019439)
This publication has 26 references indexed in Scilit:
- Short- and Long-term Outcome Following Laparoscopic Versus Open Resection for Carcinoma of the Rectum in the Multimodal SettingDiseases of the Colon & Rectum, 2012
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2012
- Interstitial Cells of CajalPancreas, 2011
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Gastrointestinal Stromal Tumors Presenting as Omental Masses—A Clinicopathologic Analysis of 95 CasesAmerican Journal of Surgical Pathology, 2009
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of OutcomeLaboratory Investigation, 2000